Compare on seven verifiable items rather than on rank: who holds the prescribing license, whether a clinician genuinely reviews the case, brand or compounded medication, which pharmacy dispenses, what the fee covers, how dose changes are handled, and how cancellation works. Each can be checked before payment. A ranking cannot.
Why ranked lists answer the wrong question
Most “best provider” pages order the field by price and shipping speed, because those are the two attributes a writer can collect without contacting anyone. Neither predicts whether a person stays on treatment for a year. The variables that do predict it are clinical and contractual, and the right answer changes by person. Someone taking three other prescriptions needs a different level of oversight than someone taking none.
Ranking also assumes there is one field. There is not. Ro, Hims and Hers, Found, Henry Meds, Mochi, and Eden operate cash-pay telehealth that routes prescriptions to partner pharmacies. Noom and Calibrate grew out of behavior-change coaching and add medication management to a lifestyle program. LillyDirect and NovoCare Pharmacy are manufacturer channels selling the approved brand products at self-pay rates rather than clinical services. Putting all of them in one numbered order hides the distinctions that actually decide the outcome.
Sorting that field by category is more useful than ordering it. Manufacturer pharmacies like LillyDirect and NovoCare sell the approved brand products directly, cash-pay telehealth groups such as Ro and Hims and Hers route prescriptions to partner pharmacies, and other providers including HealthRX post their GLP-1 medications and prices for a person to weigh in advance. Judging each against the same verifiable items reveals more than any published order does.
Item one: who prescribes, and in which state
A prescription for a GLP-1 medication has to come from a clinician licensed in the state where the patient is located at the time of the visit. Ask for the clinician’s name and credential before paying. Programs that answer with “our medical team” and nothing more are describing a process, not a person, and there is no way to verify a process.
The follow-up question is whether the intake questionnaire is read by that clinician or screened by software with a signature applied afterward. Both models exist. Obesity pharmacotherapy guidance from clinical societies treats the medication as one component of a supervised plan that includes screening for contraindications such as personal or family history of medullary thyroid carcinoma, which is a decision requiring a person, not a form.
Item two: brand product or compounded preparation
This is the largest single fork in the market and the one most often blurred. Wegovy, Zepbound, Ozempic, and Mounjaro are FDA-approved products with approved labeling. Compounded semaglutide and compounded tirzepatide are preparations made by a pharmacy, and they are not FDA-approved. The agency has not evaluated those preparations for safety, effectiveness, or manufacturing quality, and it has published specific concerns about unapproved GLP-1 products sold for weight loss.
That distinction does not make compounded care improper. It operates inside a defined legal framework with licensed prescribers and licensed pharmacies, and for people who cannot reach the brand price it is often the only route available. It does mean the price difference is not a discount on an identical item, and a provider that will not state plainly which pathway it uses has answered the question by declining to.
Item three: the dispensing pharmacy
Medication does not come from the website. It comes from a pharmacy the website has contracted with. A provider should name that pharmacy on request, along with the state it is licensed in and whether it is a traditional compounding pharmacy or a registered outsourcing facility. Those two categories sit under different sections of federal law and different manufacturing expectations, and registration with the FDA is a filing status rather than an endorsement of any product.
Item four through seven: money, dose, contact, and exit
The remaining items are contractual. What does the monthly figure include, does it rise when the dose rises, who answers a message about side effects and within what window, and what does leaving cost. Published cash pricing makes the first two checkable in advance, and providers vary widely in how much they post. Among cash-pay compounded programs, Henry Meds, Mochi, Eden, and FormBlends publish per-month figures, while several larger platforms show a starting rate and hold the rest until after intake. Either approach can be legitimate, but only the first lets a person do the arithmetic before committing.
| Evaluation item | What to verify before paying | Why it changes the outcome |
|---|---|---|
| Prescriber licensure | Name, credential, and licensing state of the clinician who signs | Establishes who is accountable and whether records transfer |
| Medication pathway | Brand product or compounded preparation, stated in writing | Compounded preparations are not FDA-approved |
| Dispensing pharmacy | Pharmacy name, licensing state, and regulatory category | Sets the standard the preparation is made under |
| Fee scope | Whether visits, labs, shipping, and supplies are included | Unbundled items reappear later as separate charges |
| Dose handling | Whether escalation costs more and how approval is timed | Every regimen escalates, so the entry price misleads |
| Clinical contact | Response window for side effects and who replies | Dose intolerance is a common reason people stop |
| Exit terms | Notice period, prepaid refunds, release of records | Decides the cost of leaving and continuity of care |
What the trial evidence settles, and what it does not
Randomized trial data describes molecules, not vendors. Semaglutide in its registration trial produced roughly 15 percent mean body weight reduction over 68 weeks. Tirzepatide in a separate trial produced roughly 21 percent at the top dose over 72 weeks. Different studies with different populations, so those figures indicate direction rather than a measured gap, and a later randomized comparison of the two molecules reported greater average reduction with tirzepatide.
None of that identifies a provider. What it does establish is that the tirzepatide programs cost more for a reason, and that treatment effect depends on reaching and holding a therapeutic dose. A program that makes escalation slow or expensive is working against the mechanism it sells.
Frequently asked questions
Is a provider with a lower price automatically the weaker option?
No. Price reflects the medication pathway and how much service is bundled, not clinical quality on its own. A compounded program will normally sit below a brand channel because the products are regulated differently. The question worth asking is what the lower figure excludes, not whether low is suspicious.
How can a prescriber’s license be checked independently?
Every state maintains a public license lookup for physicians, nurse practitioners, and physician assistants. Searching the clinician’s name in the state where they claim to practice returns license status, issue date, and any disciplinary history. It takes a few minutes and works regardless of what the provider’s own site says.
Does insurance change which provider makes sense?
Considerably. Where a plan covers anti-obesity medication, the copay route can undercut every cash program, though it usually requires prior authorization and documented criteria. Medicare drug coverage has historically excluded agents used for weight loss alone, which is a large part of why the cash market exists at all.
What if the same clinician never appears twice?
Rotating clinicians is common in telehealth and is not disqualifying by itself, provided the chart travels with the patient and whoever responds can see the full history. The problem case is a program where nobody holds continuity and each message starts the assessment over from the beginning.
Should the checklist change for someone switching providers mid-course?
The items stay the same, with one addition: timing. A new prescriber issues a new prescription after their own intake, so the practical risk is a supply gap that interrupts an escalation schedule. Starting the second intake before the current supply runs out avoids most of it.
